Bhattacharya Sankha, Kumar Devendra, Prajapati Bhuphendra G, Anjum Md Meraj
Department of Pharmaceutics, School of Pharmacy & Technology Management, SVKM'S NMIMS Deemed-to-be University, Shirpur, Maharashtra, 425405, India.
Department of Pharmaceutical Chemistry, School of Pharmacy & Technology Management, SVKM'S NMIMS Deemed-to-be University, Shirpur, Maharashtra, 425405, India.
Curr Med Chem. 2025;32(26):5493-5517. doi: 10.2174/0109298673312968240803104252.
A notable breakthrough in the treatment of colon cancer involves the utilisation of a cutting-edge drug delivery technology known as biosurfactant-derived nanomicelles. These nanomicelles, composed of natural biosurfactant molecules, possess the distinct capability to enclose pharmaceuticals or genetic material, such as DNA, siRNA, or mRNA, within spherical formations. With a size ranging from 10 to 100 nanometers, these nanomicelles exhibit precision targeting capabilities towards colon cancer cells, hence minimising the occurrence of side effects typically associated with treatment. Upon being specifically targeted, the nanomicelles liberate their cargo into cancer cells, resulting in enhanced therapy efficacy. This novel strategy utilises the specific attributes of the tumour microenvironment to administer precise and focused treatment. These nanomicelles improve the absorption by cells and reduce harm to healthy tissues by imitating important nutrients or utilising compounds that specifically target tumours. Furthermore, the incorporation of stimuli-responsive components allows for regulated medication release in reaction to the acidic environment seen in tumours. The review focuses on examining the use of biosurfactants and natural peptides in nanomicellar carriers as ways to fight against colon cancer. Folate-coated nanomicelles incorporating curcumin facilitate precise gene delivery, while the partnership of biosurfactants, such as surfactin from and natural peptides, enables the transportation of particular cyclopeptides into the tumour network. Peptides, similar to bombesin, direct nanomicelles to specific places, while peptides based on curcumin control the release of medicinal substances. While preclinical investigations demonstrate promise, obstacles remain in formulation and regulatory issues. However, biosurfactant-based nanomicelles, particularly folate-coated carriers loaded with curcumin, show tremendous potential in overcoming biological barriers and delivering medicines efficiently to colon cancer cells.
结肠癌治疗方面的一项显著突破涉及一种前沿药物递送技术的应用,即生物表面活性剂衍生的纳米胶束。这些纳米胶束由天然生物表面活性剂分子组成,具有独特能力,可将药物或遗传物质(如DNA、小干扰RNA或信使核糖核酸)包裹在球形结构内。这些纳米胶束大小在10至100纳米之间,对结肠癌细胞具有精准靶向能力,从而将通常与治疗相关的副作用发生率降至最低。在被特异性靶向后,纳米胶束将其所载物质释放到癌细胞中,从而提高治疗效果。这种新策略利用肿瘤微环境的特定属性进行精确且有针对性的治疗。这些纳米胶束通过模仿重要营养素或利用特异性靶向肿瘤的化合物来提高细胞吸收并减少对健康组织的损害。此外,加入刺激响应成分可使药物在肿瘤酸性环境中发生反应时实现可控释放。该综述着重研究生物表面活性剂和天然肽在纳米胶束载体中作为对抗结肠癌手段的应用。载有姜黄素的叶酸包被纳米胶束有助于精确的基因递送,而生物表面活性剂(如来自[具体来源未提及]的表面活性素)与天然肽的结合可使特定环肽转运至肿瘤网络。类似于蛙皮素的肽可将纳米胶束导向特定部位,而基于姜黄素的肽则可控制药物释放。虽然临床前研究显示出前景,但在制剂和监管问题方面仍存在障碍。然而,基于生物表面活性剂的纳米胶束,特别是载有姜黄素的叶酸包被载体,在克服生物屏障并将药物有效递送至结肠癌细胞方面显示出巨大潜力。